These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 35426525)

  • 1. Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials.
    Cheng G; Liu Y; Ma R; Cheng G; Guan Y; Chen X; Wu Z; Chen T
    Nanomicro Lett; 2022 Apr; 14(1):105. PubMed ID: 35426525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular Vesicles in the Treatment of Parkinson's Disease: A Review.
    Yang X; Ma Y; Xie H; Dong S; Rao G; Yang Z; Zhang J; Wu Q
    Curr Med Chem; 2021; 28(31):6375-6394. PubMed ID: 33441061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Development of Nanomaterial-Based Drug Carriers to Overcome the Blood-Brain Barrier by Using Different Transport Mechanisms.
    Song J; Lu C; Leszek J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.
    Xie J; Shen Z; Anraku Y; Kataoka K; Chen X
    Biomaterials; 2019 Dec; 224():119491. PubMed ID: 31546096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano carriers for drug transport across the blood-brain barrier.
    Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
    J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Blood-Brain Barrier Models Using Primary Parkinson's Disease Rat Brain Endothelial Cells and Astrocytes for the Development of Central Nervous System Drug Delivery Systems.
    Cai P; Zheng Y; Sun Y; Zhang C; Zhang Q; Liu Q
    ACS Chem Neurosci; 2021 Oct; 12(20):3829-3837. PubMed ID: 34623131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases.
    Kumar A; Chaudhary RK; Singh R; Singh SP; Wang SY; Hoe ZY; Pan CT; Shiue YL; Wei DQ; Kaushik AC; Dai X
    Front Neurosci; 2020; 14():305. PubMed ID: 32425743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
    PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
    Kang YJ; Cutler EG; Cho H
    Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gold-based nanomaterials for the treatment of brain cancer.
    Tu L; Luo Z; Wu YL; Huo S; Liang XJ
    Cancer Biol Med; 2021 May; 18(2):372-87. PubMed ID: 34002583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing nanoformulation for the nose-to-brain delivery in Parkinson's disease: Advancements and barrier.
    Kiran P; Debnath SK; Neekhra S; Pawar V; Khan A; Dias F; Pallod S; Srivastava R
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1768. PubMed ID: 34825510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bio-inspired nano tools for neuroscience.
    Das S; Carnicer-Lombarte A; Fawcett JW; Bora U
    Prog Neurobiol; 2016 Jul; 142():1-22. PubMed ID: 27107796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain.
    Wu JR; Hernandez Y; Miyasaki KF; Kwon EJ
    Adv Drug Deliv Rev; 2023 Jun; 197():114820. PubMed ID: 37054953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
    Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
    Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson's Disease.
    Monge-Fuentes V; Biolchi Mayer A; Lima MR; Geraldes LR; Zanotto LN; Moreira KG; Martins OP; Piva HL; Felipe MSS; Amaral AC; Bocca AL; Tedesco AC; Mortari MR
    Sci Rep; 2021 Jul; 11(1):15185. PubMed ID: 34312413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.
    Masoudi Asil S; Ahlawat J; Guillama Barroso G; Narayan M
    Biomater Sci; 2020 Aug; 8(15):4109-4128. PubMed ID: 32638706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy.
    Desai BS; Monahan AJ; Carvey PM; Hendey B
    Cell Transplant; 2007; 16(3):285-99. PubMed ID: 17503739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.